Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 35 for:    ASSERT

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome (ASSERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04674761
Recruitment Status : Recruiting
First Posted : December 19, 2020
Last Update Posted : March 12, 2021
Sponsor:
Information provided by (Responsible Party):
Albireo

Brief Summary:
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.

Condition or disease Intervention/treatment Phase
Alagille Syndrome Drug: Odevixibat Drug: Placebo Phase 3

Detailed Description:
Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Odevixibat (A4250)
Capsules for oral administration once daily for 24 weeks.
Drug: Odevixibat
Odevixibat is a small molecule and selective inhibitor of IBAT.
Other Name: A4250

Placebo Comparator: Placebo
Capsules for oral administration (to match active) once daily for 24 weeks.
Drug: Placebo
Placebo identical in appearance to experimental drug (odevixibat).




Primary Outcome Measures :
  1. Change from Baseline in Scratching Score [ Time Frame: From baseline to Week 24 ]
    Change from baseline in scratching score to Month 6 as measured by the Albireo Observer-Reported Outcome scratching score


Secondary Outcome Measures :
  1. Serum Bile Acid Levels [ Time Frame: From baseline to Week 24 ]
    Change in serum bile acid levels from baseline to Week 24

  2. Safety and Tolerability [ Time Frame: From first dose of study drug up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first ]
    Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Genetically confirmed diagnosis of Alagille syndrome
  • History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument
  • Elevated serum bile acid level

Key Exclusion Criteria:

  • History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma)
  • History of liver transplant, or a liver transplant is planned within 6 months of randomization
  • ALT >10× upper limit of normal (ULN) at screening
  • Total bilirubin >15 × ULN at screening
  • Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04674761


Contacts
Layout table for location contacts
Contact: Albireo +1 (857) 378-2035 medinfo@albireopharma.com

Locations
Layout table for location information
United States, California
University of California - San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Joanna Curry       joanna.curry@ucsf.edu   
Principal Investigator: Philip Rosenthal, MD         
United States, New York
The Childrens Hospital at Montefiore Albert Einstein School of Medicine Recruiting
Bronx, New York, United States, 10467
Contact: Megan Leary       mleary@montefiore.org   
Contact: Trang Nguyen, NP    7187412332    trannguy@montefiore.org   
Principal Investigator: Nadia Ovchinsky, MD         
France
Hôpital Femme Mère Enfant de Lyon Recruiting
Bron, France, 69677
Contact: Audrey Trouillot    33,472,681,343    audrey.trouillot@chu-lyon.fr   
Contact: Lioara Restier    33,427,856,020    lioara.restier@chu-lyon.fr   
Sponsors and Collaborators
Albireo
Layout table for additonal information
Responsible Party: Albireo
ClinicalTrials.gov Identifier: NCT04674761    
Other Study ID Numbers: A4250-012
First Posted: December 19, 2020    Key Record Dates
Last Update Posted: March 12, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Albireo:
ALGS
Alagille syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Alagille Syndrome
Syndrome
Disease
Pathologic Processes
Cholestasis, Intrahepatic
Cholestasis
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Liver Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn